{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:40:29Z","timestamp":1761237629127,"version":"3.44.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1016\/j.ahj.2009.04.007","type":"journal-article","created":{"date-parts":[[2009,5,18]],"date-time":"2009-05-18T04:17:40Z","timestamp":1242620260000},"page":"S17-S23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"S","title":["Combined renin-angiotensin-aldosterone system inhibition in patients with chronic heart failure secondary to left ventricular systolic dysfunction"],"prefix":"10.1016","volume":"157","author":[{"given":"Alan H.","family":"Gradman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasilios","family":"Papademetriou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"author":"American Heart Association\/American Stroke Association","key":"10.1016\/j.ahj.2009.04.007_bib1"},{"key":"10.1016\/j.ahj.2009.04.007_bib2","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/jama.292.3.344","article-title":"Trends in heart failure incidence and survival in a community-based population","volume":"292","author":"Roger","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2009.04.007_bib3","first-page":"S107","article-title":"Economic impact of heart failure in the United States: time for a different approach","volume":"13","author":"O'Connell","year":"1994","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.ahj.2009.04.007_bib4","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/bmj.320.7233.495","article-title":"ABC of heart failure. Management: digoxin and other inotropes, beta blockers, and antiarrhythmic and antithrombotic treatment","volume":"320","author":"Gibbs","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.ahj.2009.04.007_bib5","first-page":"28","article-title":"Pathophysiology of heart failure: a look at the future","volume":"26","author":"Delgado","year":"1999","journal-title":"Tex Heart Inst J"},{"key":"10.1016\/j.ahj.2009.04.007_bib6","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1161\/01.CIR.97.3.282","article-title":"Chronic heart failure in the United States: a manifestation of coronary artery disease","volume":"97","author":"Gheorghiade","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2009.04.007_bib7","series-title":"Cardiovascular medicine","first-page":"888","article-title":"Other cardiomyopathies","author":"Willerson","year":"1995"},{"key":"10.1016\/j.ahj.2009.04.007_bib8","series-title":"Congestive heart failure: pathophysiology, diagnosis, and comprehensive approach to management","first-page":"11","article-title":"Overview of pathophysiology of clinical heart failure","author":"Cohn","year":"1994"},{"key":"10.1016\/j.ahj.2009.04.007_bib9","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1136\/bmj.320.7228.167","article-title":"ABC of heart failure. Pathophysiology","volume":"320","author":"Jackson","year":"2000","journal-title":"BMJ"},{"first-page":"952","year":"1995","series-title":"Cardiovascular medicine","key":"10.1016\/j.ahj.2009.04.007_bib10"},{"key":"10.1016\/j.ahj.2009.04.007_bib11","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2009.04.007_bib12","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"SOLVD Investigators","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2009.04.007_bib13","first-page":"821","article-title":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure","volume":"342","author":"Acute Infarction Ramipril Efficacy (AIRE) Study Investigators","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2009.04.007_bib14","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","article-title":"A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group","volume":"333","author":"K\u00f8ber","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2009.04.007_bib15","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1161\/01.CIR.91.10.2573","article-title":"Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy","volume":"91","author":"Greenberg","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2009.04.007_bib16","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2005.08.022","volume":"46","author":"Hunt","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2009.04.007_bib17","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2009.04.007_bib18","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2009.04.007_bib19","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2009.04.007_bib20","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1161\/01.CIR.0000146819.43235.A9","article-title":"Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials","volume":"110","author":"Young","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2009.04.007_bib21","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2009.04.007_bib22","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2009.04.007_bib23","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/01.CIR.100.10.1056","article-title":"Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study","volume":"100","author":"McKelvie","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2009.04.007_bib24","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2009.04.007_bib25","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2009.04.007_bib26","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","article-title":"Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure","volume":"100","author":"Packer","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2009.04.007_bib27","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870309002762?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870309002762?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:38:31Z","timestamp":1757569111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870309002762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["S0002870309002762"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2009.04.007","relation":{},"ISSN":["0002-8703"],"issn-type":[{"type":"print","value":"0002-8703"}],"subject":[],"published":{"date-parts":[[2009,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined renin-angiotensin-aldosterone system inhibition in patients with chronic heart failure secondary to left ventricular systolic dysfunction","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2009.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Mosby, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}